prochlorperazine (Rx)

Brand and Other Names:Compazine, Compazine Spansules, more...prochlorperazine edisylate, prochlorperazine mesylate
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 5mg
  • 10mg

suppository

  • 25mg

injectable solution

  • 5mg/mL

Severe Nausea & Vomiting

PO: Immediate-release, 5-10 mg q6-8hr; extended-release, 10 mg q12hr or 15 mg every morning

Suppository: 25 mg q12hr

IM: 5-10 mg q3-4hr; not to exceed 40 mg/day

IV: 2.5-10 mg q3-4hr; not to exceed 10 mg/dose or 40 mg/day

Severe Intraoperative Nausea & Vomiting

Prophylaxis

IM: 5-10 mg administered 1-2 hours before induction of anesthesia; may be repeated once 30 minutes after initial dose

IV: 5-10 mg administered 15-30 minutes before induction of anesthesia, repeated once before procedure if desired, or 20 mg/L administered 15-30 minutes before induction; not to exceed 30 mg/day

Psychosis

5-10 mg PO q6-8hr; slowly titrate dose q2-3days; not to exceed 150 mg/day

10-20 mg IM q2-4hr to gain control; 3-4 doses rarely needed

Dosage Forms & Strengths

tablet

  • 5mg
  • 10mg

suppository

  • 2.5mg
  • 5mg
  • 25mg

injectable solution

  • 5mg/mL

Psychotic Disorder

<2 years: Not recommended

2-6 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 20 mg/day; not to exceed 10 mg on the first day

6-12 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 25 mg/day; not to exceed 10 mg on the first day

Severe Nausea & Vomiting

<2 years: Not recommended

≥2 years (9-13 kg): 2.5 mg PO daily or q12hr; not to exceed 7.5 mg/day  

≥2 years (13.1-18 kg): 2.5 mg PO q8-12hr; not to exceed 10 mg/day

≥2 years (18.1-37 kg): 2.5 mg PO q8hr or 5 mg PO q12hr; not to exceed 15 mg/day

Not drug of choice in elderly, because of extrapyramidal symptoms

Nonpsychotic Dementia Behavior (Off-label)

Lower initial dose and adjust gradually; 2.5-5 mg/day PO; dosing interval may be increased to q8-12hr PRN; not to exceed 75 mg/day

Next:

Interactions

Interaction Checker

and prochlorperazine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (9)

            • disopyramide

              prochlorperazine and disopyramide both increase QTc interval. Contraindicated.

            • ibutilide

              prochlorperazine and ibutilide both increase QTc interval. Contraindicated.

            • indapamide

              prochlorperazine and indapamide both increase QTc interval. Contraindicated.

            • metrizamide

              prochlorperazine, metrizamide. Mechanism: unknown. Contraindicated. Risk of seizure. D/C phenothiazine 24h before admin. of metrizamide.

            • pentamidine

              prochlorperazine and pentamidine both increase QTc interval. Contraindicated.

            • pimozide

              prochlorperazine and pimozide both increase QTc interval. Contraindicated.

            • procainamide

              prochlorperazine and procainamide both increase QTc interval. Contraindicated.

            • quinidine

              prochlorperazine and quinidine both increase QTc interval. Contraindicated.

            • sotalol

              prochlorperazine and sotalol both increase QTc interval. Contraindicated.

            Serious - Use Alternative (63)

            • aminolevulinic acid oral

              aminolevulinic acid oral, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.

            • aminolevulinic acid topical

              prochlorperazine increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.

            • amiodarone

              prochlorperazine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.

            • apomorphine

              prochlorperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

            • arsenic trioxide

              prochlorperazine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.

            • artemether/lumefantrine

              prochlorperazine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

            • benzhydrocodone/acetaminophen

              benzhydrocodone/acetaminophen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).

            • bromocriptine

              prochlorperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

            • cabergoline

              prochlorperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.

            • calcium/magnesium/potassium/sodium oxybates

              prochlorperazine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

            • chlorpromazine

              chlorpromazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.

            • clarithromycin

              prochlorperazine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.

            • degarelix

              degarelix and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.

            • dofetilide

              prochlorperazine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.

            • dopamine

              prochlorperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

            • dosulepin

              prochlorperazine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.

            • dronedarone

              prochlorperazine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.

            • droperidol

              prochlorperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • epinephrine

              epinephrine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.

            • epinephrine racemic

              epinephrine racemic and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin base

              prochlorperazine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin ethylsuccinate

              prochlorperazine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin lactobionate

              prochlorperazine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin stearate

              prochlorperazine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.

            • fentanyl

              fentanyl, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.

            • fentanyl intranasal

              fentanyl intranasal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.

            • fentanyl transdermal

              fentanyl transdermal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.

            • fentanyl transmucosal

              fentanyl transmucosal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.

            • fluconazole

              prochlorperazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • fluphenazine

              fluphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.

            • formoterol

              prochlorperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

            • haloperidol

              prochlorperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • hydrocodone

              hydrocodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).

            • itraconazole

              prochlorperazine and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • ketoconazole

              prochlorperazine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • levodopa

              prochlorperazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

            • levodopa inhaled

              prochlorperazine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Phenothiazine/1st generation antipsychotics inhibit dopamine D2 receptors in varying degrees.

            • lisuride

              prochlorperazine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.

            • lofepramine

              prochlorperazine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.

            • lumefantrine

              prochlorperazine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

            • methyl aminolevulinate

              prochlorperazine, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.

            • methyldopa

              prochlorperazine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.

            • metoclopramide intranasal

              prochlorperazine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              prochlorperazine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.

            • moxifloxacin

              prochlorperazine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.

            • nilotinib

              prochlorperazine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.

            • octreotide

              prochlorperazine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.

            • octreotide (Antidote)

              prochlorperazine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.

            • perphenazine

              perphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.

            • pramipexole

              prochlorperazine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.

            • promazine

              prochlorperazine and promazine both increase QTc interval. Avoid or Use Alternate Drug.

            • promethazine

              prochlorperazine and promethazine both increase QTc interval. Avoid or Use Alternate Drug.

            • quinidine

              quinidine, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive cardiac effects.

            • ropinirole

              prochlorperazine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.

            • safinamide

              prochlorperazine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.

            • saquinavir

              saquinavir, prochlorperazine. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Increased risk of QT prolongation and cardiac arrhythmias.

            • selinexor

              selinexor, prochlorperazine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.

            • sodium oxybate

              prochlorperazine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

            • thioridazine

              prochlorperazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.

            • tretinoin

              prochlorperazine, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.

            • tretinoin topical

              prochlorperazine, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.

            • trifluoperazine

              prochlorperazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.

            • yohimbe

              yohimbe decreases effects of prochlorperazine by pharmacodynamic antagonism. Contraindicated.

            • ziprasidone

              prochlorperazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.

            Monitor Closely (268)

            • abobotulinumtoxinA

              abobotulinumtoxinA increases effects of prochlorperazine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

            • aclidinium

              aclidinium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • albiglutide

              prochlorperazine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.

            • albuterol

              prochlorperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • alfentanil

              alfentanil and prochlorperazine both increase sedation. Use Caution/Monitor.

            • alprazolam

              alprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • amifampridine

              prochlorperazine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

            • amitriptyline

              prochlorperazine and amitriptyline both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and amitriptyline both increase sedation. Use Caution/Monitor.

            • amobarbital

              amobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.

            • amoxapine

              prochlorperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and amoxapine both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and amoxapine both increase sedation. Use Caution/Monitor.

            • anticholinergic/sedative combos

              anticholinergic/sedative combos decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              anticholinergic/sedative combos decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • apomorphine

              prochlorperazine and apomorphine both increase sedation. Use Caution/Monitor.

            • arformoterol

              prochlorperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • aripiprazole

              aripiprazole and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              aripiprazole and prochlorperazine both increase sedation. Use Caution/Monitor.

            • armodafinil

              prochlorperazine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • artemether/lumefantrine

              artemether/lumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

            • atracurium

              atracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              atracurium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • atropine

              atropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              atropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • atropine IV/IM

              prochlorperazine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              atropine IV/IM decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              atropine IV/IM decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

            • azelastine

              azelastine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • azithromycin

              prochlorperazine and azithromycin both increase QTc interval. Use Caution/Monitor.

            • baclofen

              baclofen and prochlorperazine both increase sedation. Use Caution/Monitor.

            • belladonna alkaloids

              belladonna alkaloids decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              belladonna alkaloids decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • belladonna and opium

              belladonna and opium and prochlorperazine both increase sedation. Use Caution/Monitor.

              belladonna and opium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              belladonna and opium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • benperidol

              benperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              benperidol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • benzphetamine

              prochlorperazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, benzphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • benztropine

              prochlorperazine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .

            • brexanolone

              brexanolone, prochlorperazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.

            • brompheniramine

              brompheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • buprenorphine

              buprenorphine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • buprenorphine buccal

              buprenorphine buccal and prochlorperazine both increase sedation. Use Caution/Monitor.

            • buprenorphine, long-acting injection

              prochlorperazine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.

            • bupropion

              bupropion will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

              prochlorperazine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.

            • butabarbital

              butabarbital and prochlorperazine both increase sedation. Use Caution/Monitor.

            • butalbital

              butalbital and prochlorperazine both increase sedation. Use Caution/Monitor.

            • butorphanol

              butorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • caffeine

              prochlorperazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • carbinoxamine

              carbinoxamine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • carisoprodol

              carisoprodol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • cenobamate

              cenobamate, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor.

            • chloral hydrate

              chloral hydrate and prochlorperazine both increase sedation. Use Caution/Monitor.

            • chlordiazepoxide

              chlordiazepoxide and prochlorperazine both increase sedation. Use Caution/Monitor.

            • chlorpheniramine

              chlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • chlorpromazine

              chlorpromazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              chlorpromazine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • chlorzoxazone

              chlorzoxazone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • cigarette smoking

              cigarette smoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.

            • cinnarizine

              cinnarizine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • cisatracurium

              cisatracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              cisatracurium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • citalopram

              citalopram and prochlorperazine both increase serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.

            • clemastine

              clemastine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • clobazam

              prochlorperazine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

            • clomipramine

              prochlorperazine and clomipramine both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and clomipramine both increase sedation. Use Caution/Monitor.

            • clonazepam

              clonazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • clonidine

              clonidine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.

            • clorazepate

              clorazepate and prochlorperazine both increase sedation. Use Caution/Monitor.

            • clozapine

              clozapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              clozapine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • codeine

              codeine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • cyclizine

              cyclizine and prochlorperazine both increase sedation. Use Caution/Monitor.

              cyclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              cyclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • cyclobenzaprine

              cyclobenzaprine and prochlorperazine both increase sedation. Use Caution/Monitor.

              cyclobenzaprine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              cyclobenzaprine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • cyproheptadine

              cyproheptadine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dantrolene

              dantrolene and prochlorperazine both increase sedation. Use Caution/Monitor.

            • darifenacin

              darifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              darifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • dasatinib

              prochlorperazine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.

            • deferoxamine

              deferoxamine, prochlorperazine. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Synergistic increase in neurological adverse effects.

            • desflurane

              desflurane and prochlorperazine both increase sedation. Use Caution/Monitor.

              desflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor.

            • desipramine

              prochlorperazine and desipramine both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and desipramine both increase sedation. Use Caution/Monitor.

            • desvenlafaxine

              desvenlafaxine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg

            • deutetrabenazine

              prochlorperazine and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.

              deutetrabenazine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.

            • dexchlorpheniramine

              dexchlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dexfenfluramine

              prochlorperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • dexmedetomidine

              dexmedetomidine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dexmethylphenidate

              prochlorperazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • dextroamphetamine

              prochlorperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • dextromoramide

              dextromoramide and prochlorperazine both increase sedation. Use Caution/Monitor.

            • diamorphine

              diamorphine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • diazepam

              diazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dicyclomine

              dicyclomine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              dicyclomine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • diethylpropion

              prochlorperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • difenoxin hcl

              difenoxin hcl and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dimenhydrinate

              dimenhydrinate and prochlorperazine both increase sedation. Use Caution/Monitor.

            • diphenhydramine

              diphenhydramine and prochlorperazine both increase sedation. Use Caution/Monitor.

              diphenhydramine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              diphenhydramine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • diphenoxylate hcl

              diphenoxylate hcl and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dipipanone

              dipipanone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • dobutamine

              prochlorperazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • dolasetron

              prochlorperazine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.

            • dopamine

              prochlorperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • dopexamine

              prochlorperazine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dosulepin

              prochlorperazine and dosulepin both increase sedation. Use Caution/Monitor.

            • doxepin

              prochlorperazine and doxepin both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and doxepin both increase sedation. Use Caution/Monitor.

            • doxylamine

              doxylamine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • droperidol

              droperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • ephedrine

              prochlorperazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • epinephrine

              prochlorperazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

              prochlorperazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.

            • epinephrine racemic

              prochlorperazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.

            • estazolam

              estazolam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • ethanol

              prochlorperazine and ethanol both increase sedation. Use Caution/Monitor.

            • etomidate

              etomidate and prochlorperazine both increase sedation. Use Caution/Monitor.

            • fenfluramine

              prochlorperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • fesoterodine

              fesoterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              fesoterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • flavoxate

              flavoxate decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              flavoxate decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • flecainide

              prochlorperazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.

            • fluoxetine

              fluoxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

              prochlorperazine and fluoxetine both increase QTc interval. Use Caution/Monitor.

            • fluphenazine

              fluphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              fluphenazine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • flurazepam

              flurazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • fluvoxamine

              fluvoxamine and prochlorperazine both increase QTc interval. Use Caution/Monitor.

            • formoterol

              prochlorperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • foscarnet

              prochlorperazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.

            • glycopyrrolate

              prochlorperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • glycopyrrolate inhaled

              glycopyrrolate inhaled decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              glycopyrrolate inhaled decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • glycopyrronium tosylate topical

              glycopyrronium tosylate topical, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

            • guanfacine

              guanfacine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.

            • haloperidol

              haloperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              haloperidol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • henbane

              henbane decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              henbane decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • homatropine

              homatropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              homatropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • hydromorphone

              hydromorphone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • hydroxyzine

              hydroxyzine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • hyoscyamine

              hyoscyamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              hyoscyamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • hyoscyamine spray

              prochlorperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              hyoscyamine spray decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              hyoscyamine spray decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

            • iloperidone

              iloperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.

              iloperidone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • imipramine

              prochlorperazine and imipramine both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and imipramine both increase sedation. Use Caution/Monitor.

            • incobotulinumtoxinA

              prochlorperazine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

            • insulin degludec

              prochlorperazine decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.

            • insulin degludec/insulin aspart

              prochlorperazine decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.

            • insulin inhaled

              prochlorperazine decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.

            • ipratropium

              ipratropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              ipratropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • isoproterenol

              prochlorperazine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, isoproterenol. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • ketamine

              ketamine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • ketotifen, ophthalmic

              prochlorperazine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

            • lapatinib

              prochlorperazine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.

            • lasmiditan

              lasmiditan, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

            • lemborexant

              lemborexant, prochlorperazine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

            • levalbuterol

              prochlorperazine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • levofloxacin

              prochlorperazine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

            • levorphanol

              levorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • liraglutide

              prochlorperazine, liraglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.

            • lisdexamfetamine

              prochlorperazine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, lisdexamfetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • lithium

              lithium, prochlorperazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.

            • lofepramine

              prochlorperazine and lofepramine both increase sedation. Use Caution/Monitor.

            • lofexidine

              prochlorperazine and lofexidine both increase sedation. Use Caution/Monitor.

            • loprazolam

              loprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • lorazepam

              lorazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • lormetazepam

              lormetazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • loxapine

              loxapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              loxapine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • loxapine inhaled

              loxapine inhaled and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              loxapine inhaled and prochlorperazine both increase sedation. Use Caution/Monitor.

            • lumefantrine

              lumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

            • lurasidone

              lurasidone, prochlorperazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

            • maprotiline

              prochlorperazine and maprotiline both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and maprotiline both increase sedation. Use Caution/Monitor.

            • marijuana

              prochlorperazine and marijuana both increase sedation. Use Caution/Monitor.

            • meclizine

              meclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              meclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • melatonin

              prochlorperazine and melatonin both increase sedation. Use Caution/Monitor.

            • meperidine

              meperidine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • meprobamate

              prochlorperazine and meprobamate both increase sedation. Use Caution/Monitor.

            • metaproterenol

              prochlorperazine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • metaxalone

              metaxalone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • metformin

              prochlorperazine decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor. Patient should be closely observed for loss of blood glucose control; when drugs are withdrawn from a patient receiving metformin, patient should be observed closely for hypoglycemia.

            • methadone

              prochlorperazine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.

              methadone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • methamphetamine

              prochlorperazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, methamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • methocarbamol

              methocarbamol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • methoxsalen

              methoxsalen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.

            • methscopolamine

              methscopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              methscopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • methylenedioxymethamphetamine

              prochlorperazine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, methylenedioxymethamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • methylphenidate

              prochlorperazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • metoclopramide

              prochlorperazine and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

            • midazolam

              midazolam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • midazolam intranasal

              midazolam intranasal, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

            • midodrine

              prochlorperazine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, midodrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • mirtazapine

              prochlorperazine and mirtazapine both increase sedation. Use Caution/Monitor.

            • modafinil

              prochlorperazine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • morphine

              morphine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • motherwort

              prochlorperazine and motherwort both increase sedation. Use Caution/Monitor.

            • moxonidine

              prochlorperazine and moxonidine both increase sedation. Use Caution/Monitor.

            • nabilone

              prochlorperazine and nabilone both increase sedation. Use Caution/Monitor.

            • nalbuphine

              nalbuphine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • norepinephrine

              prochlorperazine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, norepinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • nortriptyline

              prochlorperazine and nortriptyline both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and nortriptyline both increase sedation. Use Caution/Monitor.

            • ofloxacin

              prochlorperazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

            • olanzapine

              olanzapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              olanzapine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • oliceridine

              oliceridine, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).

            • onabotulinumtoxinA

              onabotulinumtoxinA decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              onabotulinumtoxinA decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • opium tincture

              opium tincture and prochlorperazine both increase sedation. Use Caution/Monitor.

            • orphenadrine

              orphenadrine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • oxazepam

              oxazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • oxybutynin

              oxybutynin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              oxybutynin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • oxybutynin topical

              oxybutynin topical decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              oxybutynin topical decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • oxybutynin transdermal

              oxybutynin transdermal decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              oxybutynin transdermal decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • oxycodone

              oxycodone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • oxymorphone

              oxymorphone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • paliperidone

              paliperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.

              paliperidone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • pancuronium

              pancuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              pancuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • papaveretum

              papaveretum and prochlorperazine both increase sedation. Use Caution/Monitor.

            • papaverine

              prochlorperazine and papaverine both increase sedation. Use Caution/Monitor.

            • paroxetine

              paroxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

              prochlorperazine and paroxetine both increase QTc interval. Use Caution/Monitor.

            • pazopanib

              prochlorperazine and pazopanib both increase QTc interval. Use Caution/Monitor.

            • pentazocine

              pentazocine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • pentobarbital

              pentobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.

            • perphenazine

              perphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              perphenazine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • phendimetrazine

              prochlorperazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, phendimetrazine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • phenobarbital

              phenobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.

            • phentermine

              prochlorperazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, phentermine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • phenylephrine

              prochlorperazine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, phenylephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • phenylephrine PO

              prochlorperazine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              prochlorperazine, phenylephrine PO. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • pholcodine

              prochlorperazine and pholcodine both increase sedation. Use Caution/Monitor.

            • pimozide

              pimozide and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              pimozide and prochlorperazine both increase sedation. Use Caution/Monitor.

            • pirbuterol

              prochlorperazine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • porfimer

              prochlorperazine, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.

            • posaconazole

              prochlorperazine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.

            • pralidoxime

              pralidoxime decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              pralidoxime decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • primidone

              primidone and prochlorperazine both increase sedation. Use Caution/Monitor.

            • procarbazine

              procarbazine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Excessive sedation.

            • promethazine

              prochlorperazine and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              promethazine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • propafenone

              propafenone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

            • propantheline

              propantheline decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              propantheline decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • propofol

              propofol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • propylhexedrine

              prochlorperazine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, propylhexedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • protriptyline

              prochlorperazine and protriptyline both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and protriptyline both increase sedation. Use Caution/Monitor.

            • pseudoephedrine

              prochlorperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

            • quazepam

              quazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • quetiapine

              prochlorperazine and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and quetiapine both increase sedation. Use Caution/Monitor.

            • quinidine

              quinidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

            • ramelteon

              prochlorperazine and ramelteon both increase sedation. Use Caution/Monitor.

            • ranolazine

              prochlorperazine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.

            • rapacuronium

              rapacuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              rapacuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • rimabotulinumtoxinB

              prochlorperazine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

            • risperidone

              prochlorperazine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.

              prochlorperazine and risperidone both increase sedation. Use Caution/Monitor.

            • rocuronium

              rocuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              rocuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • salmeterol

              prochlorperazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • scopolamine

              scopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              scopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • scullcap

              prochlorperazine and scullcap both increase sedation. Use Caution/Monitor.

            • secobarbital

              secobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.

            • sevoflurane

              sevoflurane and prochlorperazine both increase sedation. Use Caution/Monitor.

            • shepherd's purse

              prochlorperazine and shepherd's purse both increase sedation. Use Caution/Monitor.

            • smoking

              smoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.

            • solifenacin

              solifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              solifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • stiripentol

              stiripentol, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

            • sufentanil

              sufentanil and prochlorperazine both increase sedation. Use Caution/Monitor.

            • sulfamethoxazole

              prochlorperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.

            • tapentadol

              tapentadol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • teduglutide

              teduglutide increases levels of prochlorperazine by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.

            • telavancin

              prochlorperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

            • temazepam

              temazepam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • terbutaline

              prochlorperazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • tetrabenazine

              prochlorperazine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.

            • thioridazine

              prochlorperazine and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and thioridazine both increase sedation. Use Caution/Monitor.

            • thiothixene

              prochlorperazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and thiothixene both increase sedation. Use Caution/Monitor.

            • tiotropium

              tiotropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              tiotropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • tobacco use

              tobacco use decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.

            • tolterodine

              tolterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              tolterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • topiramate

              prochlorperazine and topiramate both increase sedation. Modify Therapy/Monitor Closely.

            • tramadol

              tramadol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • trazodone

              prochlorperazine and trazodone both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and trazodone both increase sedation. Use Caution/Monitor.

            • triazolam

              triazolam and prochlorperazine both increase sedation. Use Caution/Monitor.

            • triclofos

              triclofos and prochlorperazine both increase sedation. Use Caution/Monitor.

            • trifluoperazine

              prochlorperazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and trifluoperazine both increase sedation. Use Caution/Monitor.

            • trihexyphenidyl

              trihexyphenidyl decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.

            • trimethoprim

              prochlorperazine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.

            • trimipramine

              prochlorperazine and trimipramine both increase QTc interval. Use Caution/Monitor.

              prochlorperazine and trimipramine both increase sedation. Use Caution/Monitor.

            • triprolidine

              triprolidine and prochlorperazine both increase sedation. Use Caution/Monitor.

            • tropisetron

              prochlorperazine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.

            • trospium chloride

              trospium chloride decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              trospium chloride decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • vecuronium

              vecuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              vecuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

              prochlorperazine increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • venlafaxine

              venlafaxine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

              prochlorperazine and venlafaxine both increase QTc interval. Use Caution/Monitor.

            • voriconazole

              prochlorperazine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.

            • xylometazoline

              prochlorperazine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, xylometazoline. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • yohimbine

              prochlorperazine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              prochlorperazine, yohimbine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • ziconotide

              prochlorperazine and ziconotide both increase sedation. Use Caution/Monitor.

            • ziprasidone

              prochlorperazine and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and ziprasidone both increase sedation. Use Caution/Monitor.

            • zolpidem

              prochlorperazine will increase the level or effect of zolpidem by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Additive effect of decreased alertness and psychomotor performance

            • zotepine

              prochlorperazine and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              prochlorperazine and zotepine both increase sedation. Use Caution/Monitor.

            Minor (60)

            • amiodarone

              amiodarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • amitriptyline

              amitriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              amitriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • amoxapine

              amoxapine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              amoxapine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • asenapine

              asenapine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • atropine

              prochlorperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.

            • atropine IV/IM

              prochlorperazine increases toxicity of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.

            • benazepril

              prochlorperazine increases effects of benazepril by unspecified interaction mechanism. Minor/Significance Unknown. Enhanced hypotensive effects.

            • brimonidine

              brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

            • captopril

              prochlorperazine increases effects of captopril by unspecified interaction mechanism. Minor/Significance Unknown.

            • celecoxib

              celecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • chasteberry

              chasteberry decreases effects of prochlorperazine by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).

            • chloroquine

              chloroquine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

              chloroquine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.

            • cimetidine

              cimetidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • clomipramine

              clomipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              clomipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • darifenacin

              darifenacin will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • desipramine

              desipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • diphenhydramine

              diphenhydramine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • doxepin

              doxepin, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              doxepin, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • dronedarone

              dronedarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • duloxetine

              duloxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • enalapril

              prochlorperazine increases effects of enalapril by unspecified interaction mechanism. Minor/Significance Unknown.

            • ethanol

              ethanol, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.

            • eucalyptus

              prochlorperazine and eucalyptus both increase sedation. Minor/Significance Unknown.

            • fosinopril

              prochlorperazine increases effects of fosinopril by unspecified interaction mechanism. Minor/Significance Unknown.

            • glycopyrrolate

              prochlorperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.

            • glycopyrrolate inhaled

              prochlorperazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.

            • haloperidol

              haloperidol will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • imatinib

              imatinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • imidapril

              prochlorperazine increases effects of imidapril by unspecified interaction mechanism. Minor/Significance Unknown.

            • imipramine

              imipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              imipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • lisinopril

              prochlorperazine increases effects of lisinopril by unspecified interaction mechanism. Minor/Significance Unknown.

            • lofepramine

              lofepramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              lofepramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • maprotiline

              maprotiline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              maprotiline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • maraviroc

              maraviroc will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • marijuana

              marijuana will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • metyrapone

              prochlorperazine decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.

            • metyrosine

              metyrosine increases toxicity of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased extrapyramidal symptoms.

            • moexipril

              prochlorperazine increases effects of moexipril by unspecified interaction mechanism. Minor/Significance Unknown.

            • nilotinib

              nilotinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • nortriptyline

              nortriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              nortriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • oxybutynin

              oxybutynin increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.

            • oxybutynin topical

              oxybutynin topical increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.

            • oxybutynin transdermal

              oxybutynin transdermal increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.

            • parecoxib

              parecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • perindopril

              prochlorperazine increases effects of perindopril by unspecified interaction mechanism. Minor/Significance Unknown.

            • perphenazine

              perphenazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • protriptyline

              protriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              protriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            • pyrimethamine

              pyrimethamine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.

            • quinacrine

              quinacrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • quinapril

              prochlorperazine increases effects of quinapril by unspecified interaction mechanism. Minor/Significance Unknown.

            • ramipril

              prochlorperazine increases effects of ramipril by unspecified interaction mechanism. Minor/Significance Unknown.

            • ranolazine

              ranolazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • ritonavir

              ritonavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • sage

              prochlorperazine and sage both increase sedation. Minor/Significance Unknown.

            • sertraline

              sertraline will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • thioridazine

              thioridazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • tipranavir

              tipranavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

            • trandolapril

              prochlorperazine increases effects of trandolapril by unspecified interaction mechanism. Minor/Significance Unknown.

            • trazodone

              trazodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              trazodone, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

            • trimipramine

              trimipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.

              trimipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

            Previous
            Next:

            Adverse Effects

            <1%

            Insomnia

            Restlessness (immediate restlessness or agitation may be treated with diphenhydramine 25 mg IV push)

            Dizziness

            Anxiety

            Euphoria

            Agitation

            Depression

            Weakness

            Headache

            Cerebral edema

            Poikilothermia

            Orthostatic hypotension (after IM injection)

            Tachycardia

            ECG changes

            Anorexia

            Dyspepsia

            Constipation

            Diarrhea

            Ileus

            Blood dyscrasia

            Galactorrhea

            Gynecomastia

            Ejaculatory disorder

            Lens opacities (with prolonged use)

            Photosensitivity

            Pruritus

            Frequency Not Defined

            Akathisia

            Sedation

            Anticholinergic effects

            Weight gain

            Oligomenorrhea or amenorrhea

            Erectile dysfunction

            Extrapyramidal symptoms (muscle stiffness, dystonia, parkinsonism, tardive dyskinesia)

            Neuroleptic malignant syndrome (infrequent but serious)

            Seizure

            Decreased gag reflex

            Confusion

            Hypotension

            Hypertension

            Leukopenia

            Agranulocytosis

            Cholestatic jaundice

            Photosensitivity reaction

            Priapism

            Hepatotoxicity

            Previous
            Next:

            Warnings

            Black Box Warnings

            Patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death, as shown in short-term controlled trials; the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature

            This drug is not approved for treatment of patients with dementia-related psychosis

            Contraindications

            Documented hypersensitivity to phenothiazines

            Coma, severe CNS depression, concurrent use of large amounts of CNS depressants, poorly controlled seizure disorder, subcortical brain damage

            Postoperative management of nausea/vomiting following pediatric surgery

            Children <2 years or weighing <9 kg

            Cautions

            Avoid using in children with suspected Reye syndrome

            Use caution in evere hypertension, severe cardiovascular disease

            Use with caution in glaucoma, prostatic hypertrophy, stenosing peptic ulcer disease, history of neuroleptic malignant syndrome, Parkinson disease, hypocalcemia, renal/hepatic impairment, history of severe reactions to insulin or electroconvulsive therapy, history of seizures, asthma, respiratory tract infections, cardiovascular disease, myelosuppression

            Blood dyscrasias including neutropenia, agranulocytosis, and leukopenia reported with use; discontinue therapy at first sign of blood dyscrasias

            Risk of extrapyramidal symptoms, neuroleptic malignant syndrome, hypotension (may be particularly severe in patients with pheochromocytoma or mitral insufficiency)

            Esophageal dysmotility/aspiration may occur; use with caution in patients at risk of pneumonia

            Depresses hypothalamic thermoregulatory mechanism; exposure to extreme temperatures may cause hypo- or hyperthermia

            May alter cardiac conduction; life-threatening arrhythmias reported with therapeutic doses

            May cause anticholinergic effects (constipation, xerostomia, urinary retention, blurred vision); use caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problems

            May cause pigmentary retinopathy and lenticular and corneal deposits, especially in prolonged therapy

            May cause sedation and impair ability to perform tasks which require mental alertness, including operating heavy machinery

            Use associated with increased prolactin levels

            In case of severe hypotension, use norepinephrine or phenylepinephrine; do not use epinephrine or dopamine

            Do not crush extended-release product

            Avoid SC administration (may cause irritation)

            Antiemetic effect may obscure toxicity of chemotherapeutic drugs

            Use may be associated with neuroleptic malignant syndrome; monitor muscle rigidity, mental status changes, fever, autonomic instability

            May need anticholinergic antiparkinsonian agent to counter extrapyramidal symptoms

            May impair core body temperature regulation

            FDA warning regarding off-label use for dementia in elderly

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Phenothiazines may be excreted in breast milk; do not nurse

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Antiemetic: Antidopaminergic effect, blocking dopamine receptors in the brain, blocking vagus nerve in GI tract

            Antipsychotic: Blocking mesolimbic dopamine receptors, and blocking alpha-adrenergic receptors (D1 and D2) in brain

            Absorption

            Bioavailability: 12.5%

            Onset: 10-20 min (IM); 30-40 min (PO); 60 min (PR)

            Duration: 3-4 hr (PO); 3-12hr (PR); extended-release, 10-12 hr

            Distribution

            Vd: 1400-1548 L

            Metabolism

            Metabolized by liver

            Metabolites: N-desmethyl prochlorperazine (active)

            Elimination

            Half-life: 6.8-9 hr (PO); 6-10 hr (IV)

            Dialyzable: No

            Excretion: Feces (primarily)

            Previous
            Next:

            Administration

            IV Compatibilities

            Solution: Compatible with most common solvents

            Additive: Amikacin, ascorbic acid injection, dexamethasone, dimenhydrinate, erythromycin, ethacrynate, lidocaine, nafcillin, penicillin G potassium (incompatible at higher concentrations), sodium bicarbonate, vitamins B and C

            Syringe (partial list): Atropine, chlorpromazine, cimetidine, diphenhydramine, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, morphine sulfate (incompatible if phenol present)(?)

            Y-site (partial list): Calcium gluconate, cisplatin, cladribine, clarithromycin, cyclophosphamide, cytarabine, docetaxel, doxorubicin, doxorubicin liposomal, heparin, linezolid, melphalan, methotrexate, potassium chloride, propofol, teniposide, thiotepa, topotecan, vitamins B and C

            IV Incompatibilities

            Additive: Aminophylline, amphotericin B, ampicillin, calcium gluconate(?), chloramphenicol, chlorothiazide, floxacillin, furosemide, hydrocortisone, methohexital, penicillin G sodium, phenobarbital, thiopental

            Syringe: Dimenhydrinate, hydromorphone(?), ketorolac, midazolam, morphine tartate, pentobarbital, thiopental

            Y-site: Aldesleukin, allopurinol, amifostine, amphotericin B, aztreonam, bivalirudin, cefepime, etoposide phosphate, fenoldopam, filgrastim, fludarabine, foscarnet, gemcitabine, piperacillin/tazobactam

            IV Administration

            Avoid bolus

            IV push rate should not exceed 5 mg/min

            For infusion, dilute 20 mg in 1 L of compatible solution; may infuse over 30 minutes

            Storage

            Store at room temperature, and protect from light

            Solution is clear or slightly yellow

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            prochlorperazine Edisylate injection
            -
            5 mg/mL vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            5 mg/mL vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial
            prochlorperazine Edisylate injection
            -
            10 mg/2 mL (5 mg/mL) vial

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            prochlorperazine Edisylate injection

            NO MONOGRAPH AVAILABLE AT THIS TIME

            USES: Consult your pharmacist.

            HOW TO USE: Consult your pharmacist.

            SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Consult your pharmacist.

            DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

            NOTES: No monograph available at this time.

            MISSED DOSE: Consult your pharmacist.

            STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

            Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.